The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody drug conjugate (ADC) combinations in advanced urothelial cancer.

(UroToday.com) The 2025 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA was host to the Poster Session A: Prostate Cancer. Dr. Moein Moradpour ...

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.

After re-staging patients, ideally with PSMA-PET, and performing a biopsy to confirm the recurrence and stratify them into risk categories, it is time to discuss local salvage treatment. Options ...

Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a ...

With a new treatment for prostate cancer in play, men with more aggressive forms of prostate cancer may have a more positive ...

Among those with intermediate-risk prostate cancer, high PSA levels prior to HIFU led to an increased risk of overall ...

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

After an apparent accidental early release, Pfizer has revealed phase 1 data showing its investigational candidate, alongside ...

Bayer is committed to advancing treatment in prostate cancer care, showcasing new analyses from its comprehensive clinical trial program for NUBEQA ® (darolutamide), which includes the ARANOTE, ...